Anzeige
Mehr »
Login
Montag, 23.12.2024 Börsentäglich über 12.000 News von 679 internationalen Medien
Die erste börsennotierte Gesellschaft, die auf das gemeinsame Wachstum von Solana, XRP und Dogecoin setzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EVGP | ISIN: US89237H3084 | Ticker-Symbol: N/A
Berlin
02.07.24
08:26 Uhr
1,410 Euro
0,000
0,00 %
1-Jahres-Chart  (nicht börsennotiert)
TRACON PHARMACEUTICALS INC Chart 1 Jahr

Aktuelle News zur TRACON PHARMACEUTICALS

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.11.Tracon Pharmaceuticals, Inc. - 15-12G, Securities registration termination2
14.10.Tracon Pharmaceuticals issues super-voting share to CEO5
TRACON PHARMACEUTICALS Aktie jetzt für 0€ handeln
14.10.Tracon Pharmaceuticals gibt Super-Stimmrechtsaktie an CEO aus2
11.10.Tracon Pharmaceuticals, Inc. - 8-K, Current Report1
13.08.Tracon Pharmaceuticals, Inc. - 10-Q, Quarterly Report3
31.07.Tracon Pharmaceuticals winds down weeks after world's first injectable PD-L1 inhibitor stumbles in phase 211
30.07.TRACON Pharmaceuticals to wind down operations4
30.07.Tracon Pharmaceuticals, Inc. - 8-K, Current Report-
30.07.TRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Announces it Will Wind Down Operations211SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB: TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was...
► Artikel lesen
19.07.NSE - Tracon Pharmaceuticals, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities3
16.07.Delisting of Securities of CONX Corp.; Priveterra Acquisition Corp. II; Yield10 Bioscience, Inc.; Aesthetic Medical International Holdings Group; Breeze Holdings Acquisition Corp.; Quadro Acquisition One Corp.; DermTech, Inc.; TRACON Pharmaceuticals ...227NEW YORK, July 16, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock, units, and warrants of CONX Corp. CONX Corp.'s securities were suspended on...
► Artikel lesen
02.07.Tracon Pharmaceuticals mulls strategic options after sarcoma drug fails Phase II trial2
01.07.TRACON Pharmaceuticals ends development of envafolimab, exploring strategic options3
01.07.TRACON Pharmaceuticals Terminates Development Of Envafolimab; To Focus On Strategic Alternatives1
01.07.TRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform143The objective response rate by blinded independent central review in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders) and did not meet the primary endpoint...
► Artikel lesen
01.07.Tracon Pharmaceuticals, Inc. - 8-K, Current Report1
11.06.TRACON Pharmaceuticals, Inc.: TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients159Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical Resection, Temodar and External Beam Radiotherapy...
► Artikel lesen
14.05.TRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update160SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
► Artikel lesen
08.04.TRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Announces Reverse Stock Split315SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform...
► Artikel lesen
05.03.TRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update204SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten